Browse Tag

Aimmune's Palforzia

Nestlé successfully completed acquisition of Aimmune Therapeutics

4 mins read

THE FINANCIAL — Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc‘s global pharmaceutical business. “Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives,” said Greg Behar, CEO of NHSc. “Aimmune’s PALFORZIA®, the first medication approved for treating peanut allergy, is a game-changer and it’s only the beginning. Aimmune’s pharmaceutical expertise and infrastructure will complement our existing research and development to…

Read More »

Nestlé successfully completed acquisition of Aimmune Therapeutics

4 mins read

THE FINANCIAL — Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc‘s global pharmaceutical business. “Nestlé Health Science’s acquisition of Aimmune Therapeutics marks an important milestone in our…

Nestle announced the results of the tender offer for Aimmune

1 min read

The FINANCIAL — Société des Produits Nestlé S.A. (“Nestlé”) today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. (“Purchaser”), to purchase all of the outstanding shares (“Shares”) of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) (“Aimmune”), other than any Shares held by Nestlé and its affiliates, for a…

Nestle to buy Aimmune’s peanut allergy treatment at $2.6 billion

3 mins read

The FINANCIAL — Nestle agreed to buy Aimmune Therapeutics Inc. for $2.6 billion, adding a promising peanut allergy treatment to its portfolio of coffee, snacks and water. The Swiss owner of Nespresso will pay $34.50 a share for the U.S. biotech firm, almost triple its last closing price. Aimmune makes a therapy to help reduce allergic…